Tag: UT Health San Antonio

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial
Articles, Featured

Rapamycin Holdings Treats First Humans in eRapa Clinical Trial

Rapamycin Holdings, Inc. (RHI), a privately-held drug development company, has started treating human patients with its proprietary formulation of a ground-breaking cancer prevention drug. The San Antonio-based company is commercializing eRapa, a novel reformulation of the generic drug Rapamycin. This first human Phase 1b clinical trial of eRapa will treat men with early-stage prostate cancer. Twelve to 24 qualified patients are in the first human trials to establish safety and the optimal dose of eRapa. Michael Liss, M.D., a urologic oncologist at UT Health San Antonio MD Anderson Cancer Center, is leading the clinical trial at the center where the Phase 1b study is being conducted. The cancer center has a long history of testing cancer breakthrough therapies in their early-phase cance...
BioMed SA Recognizes PTSD Researcher for Innovation in Healthcare and Bioscience
Articles, Featured

BioMed SA Recognizes PTSD Researcher for Innovation in Healthcare and Bioscience

Combat veterans suffering from combat-related post-traumatic stress disorder (PTSD) after the Sept. 11, 2001 attacks did not have treatments tailored for the trauma they experienced because such treatment did not exist at the time. A former U.S. Air Force psychologist now based in San Antonio led efforts to develop customized PTSD treatment for combat veterans and will be recognized for his innovative work Thursday evening. BioMed SA has selected Dr. Alan Peterson as the 2018 recipient of its Award for Innovation in Healthcare and Bioscience. BioMed SA, an advocacy organization promoting San Antonio’s bioscience industry, recognizes innovators annually who have put novel ideas into action with transformational results. Peterson will receive the award Sept. 13 at the Vistas at Valero. ...